Premium
p62 is a useful predictive marker for tumour regression after chemoradiation therapy in patients with advanced rectal cancer: an immunohistochemical study
Author(s) -
Kobayashi Toshinori,
Ishida Mitsuaki,
Miki Hisanori,
Matsumi Yuki,
Fukui Toshiro,
Hamada Madoka,
Tsuta Koji,
Sekimoto Mitsugu
Publication year - 2021
Publication title -
colorectal disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.029
H-Index - 89
eISSN - 1463-1318
pISSN - 1462-8910
DOI - 10.1111/codi.15486
Subject(s) - medicine , colorectal cancer , immunohistochemistry , biopsy , staining , predictive marker , cancer , oncology , pathology , gastroenterology
Aim This study aimed to evaluate the relationship between p62 expression status and tumour regression grade in advanced rectal cancer. Methods We enrolled 47 consecutive patients with advanced rectal cancer who underwent chemoradiation therapy (CRT) before surgery. p62 expression in the biopsy specimens was immunohistochemically evaluated, and p62 expression score (staining intensity × positive tumour cells, %) was calculated (range 0–300). The relationship between p62 expression score and CRT effect was analysed. Results The staining intensity was +2 and +3 in 29 and 18 patients, respectively. The median proportion of positive neoplastic cells was 87.8%, and that of the p62 expression score was 200. Stronger staining intensity and a higher proportion of p62‐positive neoplastic cells were significantly associated with CRT non‐effectiveness ( P = 0.0002 and P = 0.0116, respectively), and a higher p62 expression score was significantly associated with CRT non‐effectiveness ( P < 0.0001). The optimal cut‐off value for predicting the CRT effect was 240. Conclusions A higher p62 expression score was significantly associated with less CRT effectiveness in patients with advanced rectal cancer. Analysis of p62 expression score using biopsy specimens is a useful and easily assessable prediction marker for CRT effect and might help select patients who can undergo a ‘watch‐and‐wait’ strategy after CRT.